This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Targeted Stat2 deletion in conventional dendritic cells impairs CTL responses but does not affect antibody production
Oncoimmunology. 2020 Dec 29;10(1) :1860477
PMID: 33457079 PMCID: PMC7781843 URL: https://www.ncbi.nlm.nih.gov/pubmed/33457079
AbstractSTAT2 is a central component of the ISGF3 transcriptional complex downstream of type I interferon (IFN-I) signaling. The significance of in vivo IFN-I/STAT1 signals in cDCs is well-established in the generation of antitumor cytotoxic T cell (CTL) responses. However, the role of STAT2 has remained elusive. Here, we report a clinical correlation between cDC markers and STAT2 associated with better survival in human metastatic melanoma. In a murine tumor transplantation model, targeted Stat2 deletion in CD11c+cDCs enhanced tumor growth unaffected by IFNβ therapy. Furthermore, STAT2 was essential for both, the activation of CD8a+cDCs and CD11b+cDCs and antigen cross-presentation in vivo for the generation of robust T cell killing response. In contrast, STAT2 in CD11c+cDCs was dispensable for stimulating an antigen-specific humoral response, which was impaired in global Stat2 deficient mice. Thus, our studies indicate that STAT2 in cDCs is critical in host IFN-I signals by sculpting CTL responses against tumors.
Notes2162-402x Qiu, Connie C Kotredes, Kevin P Cremers, Tess Patel, Sajan Afanassiev, Alexandra Slifker, Michael Gallucci, Stefania Gamero, Ana M Orcid: 0000-0001-7843-1415 Journal Article Oncoimmunology. 2020 Dec 29;10(1):1860477. doi: 10.1080/2162402X.2020.1860477.